| (Values in U.S. Thousands) | Mar, 2025 | Dec, 2024 | Sep, 2024 | Jun, 2024 | Mar, 2024 |
| Sales | 14,060 | 12,820 | 11,870 | 8,650 | 7,900 |
| Sales Growth | +9.67% | +8.00% | +37.23% | +9.49% | -89.87% |
| Net Income | -62,210 | -95,780 | -93,550 | -102,850 | -108,480 |
| Net Income Growth | +35.05% | -2.38% | +9.04% | +5.19% | -231.64% |
Sage Therapeutic Com
(SAGE)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.
Fiscal Year End Date: 12/31